Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Population pharmacokinetics of remlifanserin (ACP‐204), a serotonin 2A receptor inverse agonist
Saved in:
| Published in: | Alzheimer's & Dementia: Translational Research & Clinical Interventions |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Population pharmacokinetics of remlifanserin (ACP‐204), a serotonin 2A receptor inverse agonist
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- Reduced CB1 Cannabinoid Receptor Expression in Alzheimer's Disease and Transgenic Mouse Models
- Economic evaluations of strategies targeting pre‐diagnosis dementia populations: A systematic review
- Postural Changes on Heart Rate Variability among Older Population: A Preliminary Study
- Assessment of the Health Status of the Oldest Olds Living on the Greek Island of Ikaria: A Population Based-Study in a Blue Zone
- Subsequent Hypertension’s Mediation of the Association Between Sleep Duration Trajectories and New-Onset Cardiovascular Disease: Population-Based Cohort Study